Abstract
Regulation of the sleep-waking cycle is complex, involving multiple neurological circuits and diverse endogenous molecules. Interplay among assorted neuroanatomical and neurochemical systems such as acetylcholine, dopamine, noradrenaline, serotonin, histamine, and hypocretin maintain the waking (W) state. The sleep-onset is governed by the interacting forces of the sleep drive, which steadily increases with duration of W, and circadian fluctuations. Sleeppromoting neurons located in the anterior hypothalamus release GABA and inhibit wake-promoting regions in the hypothalamus and brainstem and participate in the generation of slow wave sleep (SWS). During rapid eye movement (REM) sleep, brainstem regions typically inhibited during W and SWS become active. In this regard, ascending projections from cholinergic neurons in the brainstem activate the thalamus which in turn increases the firing of the neurons in the cortex. Finally, sleep-promoting substances that accumulate in the brain during natural or prolonged W implicate a further complexity in the mechanism of modulation of the sleep-wake cycle. This review provides a broad understanding of our present knowledge in the field of sleep research.
Keywords: Sleep-wake cycle, neurotransmitter, brainstem, lateral hypothalamus, cortex, histamine
CNS & Neurological Disorders - Drug Targets
Title: Mechanisms of Sleep-Wake Cycle Modulation
Volume: 8 Issue: 4
Author(s): Eric Murillo-Rodriguez, Oscar Arias-Carrion, Katya Sanguino-Rodriguez, Mauricio Gonzalez-Arias and Reyes Haro
Affiliation:
Keywords: Sleep-wake cycle, neurotransmitter, brainstem, lateral hypothalamus, cortex, histamine
Abstract: Regulation of the sleep-waking cycle is complex, involving multiple neurological circuits and diverse endogenous molecules. Interplay among assorted neuroanatomical and neurochemical systems such as acetylcholine, dopamine, noradrenaline, serotonin, histamine, and hypocretin maintain the waking (W) state. The sleep-onset is governed by the interacting forces of the sleep drive, which steadily increases with duration of W, and circadian fluctuations. Sleeppromoting neurons located in the anterior hypothalamus release GABA and inhibit wake-promoting regions in the hypothalamus and brainstem and participate in the generation of slow wave sleep (SWS). During rapid eye movement (REM) sleep, brainstem regions typically inhibited during W and SWS become active. In this regard, ascending projections from cholinergic neurons in the brainstem activate the thalamus which in turn increases the firing of the neurons in the cortex. Finally, sleep-promoting substances that accumulate in the brain during natural or prolonged W implicate a further complexity in the mechanism of modulation of the sleep-wake cycle. This review provides a broad understanding of our present knowledge in the field of sleep research.
Export Options
About this article
Cite this article as:
Murillo-Rodriguez Eric, Arias-Carrion Oscar, Sanguino-Rodriguez Katya, Gonzalez-Arias Mauricio and Haro Reyes, Mechanisms of Sleep-Wake Cycle Modulation, CNS & Neurological Disorders - Drug Targets 2009; 8 (4) . https://dx.doi.org/10.2174/187152709788921654
DOI https://dx.doi.org/10.2174/187152709788921654 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Stress Rheostat: An Interplay Between the Unfolded Protein Response (UPR) and Autophagy in Neurodegeneration
Current Molecular Medicine Hepatic Encephalopathy: Cause and Possible Management with Botanicals
Recent Patents on Inflammation & Allergy Drug Discovery Role of Artificial Intelligence Techniques (Automatic Classifiers) in Molecular Imaging Modalities in Neurodegenerative Diseases
Current Alzheimer Research Pharmacological Strategies for Neuroprotection in Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Current Pharmaceutical Design Tau Pathology and Future Therapeutics
Current Alzheimer Research Non-Analgesic Effects of Opioids: Opioid-induced Respiratory Depression
Current Pharmaceutical Design A Lesson from Bombinins H, Mildly Cationic Diastereomeric Antimicrobial Peptides from Bombina Skin
Current Protein & Peptide Science Suicide in Parkinson’s Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis
Current Pharmaceutical Design The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments
Current Neuropharmacology Editorial [Hot topic:Pharmacological Brain Imaging in the Healthy and Sick Brain (Executive Editor: F.M. Van Der Veen)]
Current Pharmaceutical Design Tumor-Induced Metabolism and T Cells Located in Tumor Environment
Current Cancer Drug Targets Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Some Peculiar Effects of NO-Synthase Inhibition on the Structure and Function of Cardiovascular System
Current Pharmaceutical Biotechnology Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Investigating Optimal Echo Times for Quantitative Susceptibility Mapping of Basal Ganglia Nuclei in the Healthy Brain
Current Medical Imaging Schizophrenia and Idiopathic Unconjugated Hyperbilirubinemia (Gilberts Syndrome)
Central Nervous System Agents in Medicinal Chemistry Xanthine Derivatives as Agents Affecting Non-dopaminergic Neuroprotection in Parkinson’s Disease
Current Medicinal Chemistry